Research ExplorerPublicationsAcute myeloid leukemia derived from lympho-myeloid clonal he...

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis

Standard

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. / Thol, F; Klesse, S; Köhler, L; Gabdoulline, R; Kloos, A; Liebich, A; Wichmann, M; Chaturvedi, A; Fabisch, J; Gaidzik, V I; Paschka, P; Bullinger, L; Bug, G; Serve, H; Göhring, G; Schlegelberger, B; Lübbert, M; Kirchner, H; Wattad, M; Kraemer, D; Hertenstein, B; Heil, G; Fiedler, W; Krauter, J; Schlenk, R F; Döhner, K; Döhner, H; Ganser, A; Heuser, M.

In: LEUKEMIA, Vol. 31, No. 6, 06.2017, p. 1286-1295.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Thol, F, Klesse, S, Köhler, L, Gabdoulline, R, Kloos, A, Liebich, A, Wichmann, M, Chaturvedi, A, Fabisch, J, Gaidzik, VI, Paschka, P, Bullinger, L, Bug, G, Serve, H, Göhring, G, Schlegelberger, B, Lübbert, M, Kirchner, H, Wattad, M, Kraemer, D, Hertenstein, B, Heil, G, Fiedler, W, Krauter, J, Schlenk, RF, Döhner, K, Döhner, H, Ganser, A & Heuser, M 2017, 'Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis', LEUKEMIA, vol. 31, no. 6, pp. 1286-1295. https://doi.org/10.1038/leu.2016.345

APA

Thol, F., Klesse, S., Köhler, L., Gabdoulline, R., Kloos, A., Liebich, A., Wichmann, M., Chaturvedi, A., Fabisch, J., Gaidzik, V. I., Paschka, P., Bullinger, L., Bug, G., Serve, H., Göhring, G., Schlegelberger, B., Lübbert, M., Kirchner, H., Wattad, M., ... Heuser, M. (2017). Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. LEUKEMIA, 31(6), 1286-1295. https://doi.org/10.1038/leu.2016.345

Vancouver

Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A et al. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. LEUKEMIA. 2017 Jun;31(6):1286-1295. https://doi.org/10.1038/leu.2016.345

Bibtex

@article{dcf89a08e292462682271168b1b75a9e,
title = "Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis",
abstract = "We studied acute myeloid leukemia (AML) patients with lympho-myeloid clonal hematopoiesis (LM-CH), defined by the presence of DNA methyltransferase 3A (DNMT3A) mutations in both the myeloid and lymphoid T-cell compartment. Diagnostic, complete remission (CR) and relapse samples were sequenced for 34 leukemia-related genes in 171 DNMT3A mutated adult AML patients. AML with LM-CH was found in 40 patients (23%) and was associated with clonal hematopoiesis of indeterminate potential years before AML, older age, secondary AML and more frequent MDS-type co-mutations (TET2, RUNX1 and EZH2). In 82% of AML patients with LM-CH, the preleukemic clone was refractory to chemotherapy and was the founding clone for relapse. Both LM-CH and non-LM-CH MRD-positive AML patients who achieved CR had a high risk of relapse after 10 years (75% and 75%, respectively) compared with patients without clonal hematopoiesis in CR with negative MRD (27% relapse rate). Long-term survival of patients with LM-CH was only seen after allogeneic hematopoietic stem cell transplantation (HSCT). We define AML patients with LM-CH as a distinct high-risk group of AML patients that can be identified at diagnosis through mutation analysis in T cells and should be considered for HSCT.Leukemia advance online publication, 3 January 2017; doi:10.1038/leu.2016.345.",
author = "F Thol and S Klesse and L K{\"o}hler and R Gabdoulline and A Kloos and A Liebich and M Wichmann and A Chaturvedi and J Fabisch and Gaidzik, {V I} and P Paschka and L Bullinger and G Bug and H Serve and G G{\"o}hring and B Schlegelberger and M L{\"u}bbert and H Kirchner and M Wattad and D Kraemer and B Hertenstein and G Heil and W Fiedler and J Krauter and Schlenk, {R F} and K D{\"o}hner and H D{\"o}hner and A Ganser and M Heuser",
year = "2017",
month = jun,
doi = "10.1038/leu.2016.345",
language = "English",
volume = "31",
pages = "1286--1295",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "6",

}

RIS

TY - JOUR

T1 - Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis

AU - Thol, F

AU - Klesse, S

AU - Köhler, L

AU - Gabdoulline, R

AU - Kloos, A

AU - Liebich, A

AU - Wichmann, M

AU - Chaturvedi, A

AU - Fabisch, J

AU - Gaidzik, V I

AU - Paschka, P

AU - Bullinger, L

AU - Bug, G

AU - Serve, H

AU - Göhring, G

AU - Schlegelberger, B

AU - Lübbert, M

AU - Kirchner, H

AU - Wattad, M

AU - Kraemer, D

AU - Hertenstein, B

AU - Heil, G

AU - Fiedler, W

AU - Krauter, J

AU - Schlenk, R F

AU - Döhner, K

AU - Döhner, H

AU - Ganser, A

AU - Heuser, M

PY - 2017/6

Y1 - 2017/6

N2 - We studied acute myeloid leukemia (AML) patients with lympho-myeloid clonal hematopoiesis (LM-CH), defined by the presence of DNA methyltransferase 3A (DNMT3A) mutations in both the myeloid and lymphoid T-cell compartment. Diagnostic, complete remission (CR) and relapse samples were sequenced for 34 leukemia-related genes in 171 DNMT3A mutated adult AML patients. AML with LM-CH was found in 40 patients (23%) and was associated with clonal hematopoiesis of indeterminate potential years before AML, older age, secondary AML and more frequent MDS-type co-mutations (TET2, RUNX1 and EZH2). In 82% of AML patients with LM-CH, the preleukemic clone was refractory to chemotherapy and was the founding clone for relapse. Both LM-CH and non-LM-CH MRD-positive AML patients who achieved CR had a high risk of relapse after 10 years (75% and 75%, respectively) compared with patients without clonal hematopoiesis in CR with negative MRD (27% relapse rate). Long-term survival of patients with LM-CH was only seen after allogeneic hematopoietic stem cell transplantation (HSCT). We define AML patients with LM-CH as a distinct high-risk group of AML patients that can be identified at diagnosis through mutation analysis in T cells and should be considered for HSCT.Leukemia advance online publication, 3 January 2017; doi:10.1038/leu.2016.345.

AB - We studied acute myeloid leukemia (AML) patients with lympho-myeloid clonal hematopoiesis (LM-CH), defined by the presence of DNA methyltransferase 3A (DNMT3A) mutations in both the myeloid and lymphoid T-cell compartment. Diagnostic, complete remission (CR) and relapse samples were sequenced for 34 leukemia-related genes in 171 DNMT3A mutated adult AML patients. AML with LM-CH was found in 40 patients (23%) and was associated with clonal hematopoiesis of indeterminate potential years before AML, older age, secondary AML and more frequent MDS-type co-mutations (TET2, RUNX1 and EZH2). In 82% of AML patients with LM-CH, the preleukemic clone was refractory to chemotherapy and was the founding clone for relapse. Both LM-CH and non-LM-CH MRD-positive AML patients who achieved CR had a high risk of relapse after 10 years (75% and 75%, respectively) compared with patients without clonal hematopoiesis in CR with negative MRD (27% relapse rate). Long-term survival of patients with LM-CH was only seen after allogeneic hematopoietic stem cell transplantation (HSCT). We define AML patients with LM-CH as a distinct high-risk group of AML patients that can be identified at diagnosis through mutation analysis in T cells and should be considered for HSCT.Leukemia advance online publication, 3 January 2017; doi:10.1038/leu.2016.345.

U2 - 10.1038/leu.2016.345

DO - 10.1038/leu.2016.345

M3 - SCORING: Journal article

C2 - 27881874

VL - 31

SP - 1286

EP - 1295

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 6

ER -